MedTrace Logo

A Trial of BKM120 (a PI3K Inhibitor) in Patients With Triple Negative Metastatic Breast Cancer

NCT01629615 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 50

Last updated 2020-10-28

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to evaluate the clinical activity of BKM120 in patients with metastatic triple-negative breast cancer.

Conditions

Interventions

DRUG

BKM120

BKM120 oral capsules. 100 mg daily in cycles of 28 days, until disease progression

Sponsors & Collaborators

Principal Investigators

  • Jose Baselga, MD · Massachusetts General Hospital

  • Eric Winer, MD · Dana-Farber Cancer Institute

  • Jordi Rodon, MD · Hospital Universitario Vall d´Hebron

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-06-30
Primary Completion
2015-10-31
Completion
2015-10-31

Countries

  • United States
  • Spain

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01629615 on ClinicalTrials.gov